东亚药业拟回购注销1.4万股限制性股票，8月27日完成注销

Core Viewpoint - East Asia Pharmaceutical plans to repurchase and cancel 14,000 restricted stocks due to one incentive object voluntarily resigning, with the cancellation expected to be completed by August 27, 2025 [1][2]. Group 1: Repurchase and Cancellation Decision - On June 30, 2025, East Asia Pharmaceutical held its fourth board meeting and eighth supervisory board meeting, where the proposal for repurchasing and canceling part of the restricted stocks was approved [2]. - The repurchase involves one incentive object who no longer qualifies for the restricted stock incentive due to voluntary resignation, and the company will repurchase the stocks at the grant price [2]. - The company has opened a dedicated securities account for the repurchase and applied for the cancellation procedures with the China Securities Depository and Clearing Corporation [2]. Group 2: Changes in Share Structure - After the repurchase and cancellation, the number of restricted circulating shares will decrease from 2,156,103 shares to 2,142,103 shares [3]. - The final share structure change will be confirmed by the China Securities Depository and Clearing Corporation after the cancellation is completed [3]. Group 3: Compliance and Legal Opinions - The board of directors stated that the decision-making process and information disclosure for the repurchase and cancellation are compliant and do not harm the interests of the incentive object or creditors [4]. - The company has committed to the accuracy and completeness of the information and has informed the incentive object without objection [4]. - Shanghai Junlan Law Firm believes that the repurchase and cancellation have obtained necessary approvals and are in compliance with relevant regulations, with minimal impact on the company's finances and operations [4].